Drug intelligence / Profile preview

cannabivarin

Development stage: Unknown
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

Cannabivarin (CBV), also known as cannabivarol, is a non-psychoactive cannabinoid found in minor amounts in the hemp plant Cannabis sativa. It is an analog of cannabinol (CBN) with a shortened side chain and is formed as an oxidation product of tetrahydrocannabivarin (THCV). Unlike THC, CBV does not produce euphoric or psychoactive effects. Its pharmacological properties and potential therapeutic uses remain largely unstudied, with limited research available on its mechanism of action or clinical applications[1][2][3][8].

Other names: cannabivarol

Beyond the preview

Go deeper on cannabivarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabivarin.

Explore the full profile